Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer
Brigham and Women's Hospital · Harvard University · +1 more institution
Abstract
More than one third of men received a GnRH agonist during follow-up. GnRH agonist use was associated with increased risk of incident diabetes (adjusted hazard ratio [HR], 1.44; P .20).
GnRH agonist treatment for men with locoregional prostate cancer may be associated with an increased risk of incident diabetes and cardiovascular disease. The benefits of GnRH agonist treatment should be weighed against these potential risks. Additional research is needed to identify populations of men at highest risk of treatment-related complications and to develop strategies to prevent treatment-related diabetes and cardiovascular disease.
Citation impact
- FWCI
- 64.54
- Percentile
- 100%
- References
- 43
Authors
3- NLNancy L. KeatingCorresponding
Brigham and Women's Hospital, Harvard University, Massachusetts General Hospital
- AJA. James O’Malley
Brigham and Women's Hospital, Harvard University, Massachusetts General Hospital
- MRMatthew R. Smith
Brigham and Women's Hospital, Harvard University, Massachusetts General Hospital
Topics & keywords
- Medicine
- Prostate cancer
- Androgen deprivation therapy
- Internal medicine
- Myocardial infarction
- Diabetes mellitus
- Hazard ratio
- Population
- Good health and well-being